This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DEPO Depomed (DEPO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Depomed Stock (NASDAQ:DEPO) 30 days 90 days 365 days Advanced Chart Get Depomed alerts:Sign Up Key Stats Today's Range$7.09▼$7.4250-Day Range N/A52-Week Range$4.31▼$9.48Volume940,193 shsAverage Volume1.30 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL. Read More Receive DEPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter. Email Address DEPO Stock News HeadlinesPfizer: Investor Activism Is Not The SolutionOctober 9, 2024 | seekingalpha.comNeuropathic Pain Market Demand to Hit USD 13.16 Billion by 2033 | Globally at 5.55% CAGRSeptember 5, 2024 | finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Vulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030October 30, 2023 | finance.yahoo.comHorizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion BidAugust 29, 2023 | thestreet.comWhy DepoMed (DEPO) Stock Is Gaining TodayAugust 13, 2023 | thestreet.comSurge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028July 31, 2023 | finance.yahoo.comOpioid Litigants Get Boost From Senate ReportJuly 8, 2023 | thestreet.comSee More Headlines DEPO Stock Analysis - Frequently Asked Questions How were Depomed's earnings last quarter? Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.16 by $0.03. Depomed's revenue was down 37.0% compared to the same quarter last year. What other stocks do shareholders of Depomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Depomed investors own include Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (SBS), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP) and Bausch Health Cos (BHC). Company Calendar Last Earnings8/08/2018Today8/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DEPO CIK1005201 Webwww.depomedinc.com Phone(224) 419-7106FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:DEPO) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Depomed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Depomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
